Sagimet Biosciences initiates U.S. AURORA Phase 3 acne trial, secures $115M financing
Sagimet initiated its pivotal U.S. Phase 3 clinical trial for denifanstat amid positive Chinese results and secured $115M in gross proceeds, bolstering financial liquidity through mid-2029.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed